The FDA’s recent final guidance on presenting quantitative efficacy and risk information in direct-to-consumer (DTC) promotions is little changed from the draft guidance released nearly five years ago. The final guidance, issued June 27, covers quantitative efficacy and risk information in DTC promotional labeling and advertisements for prescription human drug and biological ... Read More